Charles Conway

2018

In 2018, Charles Conway earned a total compensation of $2.8M as Chief Scientific Officer at Biohaven Pharmaceutical Holding Co Ltd., a 72% increase compared to previous year.

Compensation breakdown

Bonus$205,163
Option Awards$2,243,800
Salary$334,960
Other$8,932
Total$2,792,855

Conway received $2.2M in option awards, accounting for 80% of the total pay in 2018.

Conway also received $205.2K in bonus, $335K in salary and $8.9K in other compensation.

Rankings

In 2018, Charles Conway's compensation ranked 4,171st out of 14,244 executives tracked by ExecPay. In other words, Conway earned more than 70.7% of executives.

ClassificationRankingPercentile
All
4,171
out of 14,244
71st
Division
Manufacturing
1,538
out of 5,765
73rd
Major group
Chemicals And Allied Products
550
out of 2,128
74th
Industry group
Drugs
460
out of 1,817
75th
Industry
Pharmaceutical Preparations
356
out of 1,391
74th
Source: SEC filing on April 11, 2019.

Conway's colleagues

We found four more compensation records of executives who worked with Charles Conway at Biohaven Pharmaceutical Holding Co Ltd. in 2018.

2018

Vlad Coric

Biohaven Pharmaceutical Holding Co Ltd.

Chief Executive Officer

2018

James Engelhart

Biohaven Pharmaceutical Holding Co Ltd.

Chief Financial Officer

2018

Kimberly Gentile

Biohaven Pharmaceutical Holding Co Ltd.

SVP, Clinical Operations

2018

John Tilton

Biohaven Pharmaceutical Holding Co Ltd.

Chief Commercial Officer

News

In-depth

You may also like